SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Dar© Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced it was selected as a spoke for the Investor Catalyst Hub, a...
Daré Bioscience inks royalty deal with XOMA: The company received $22 million, which is expected to help progress a pair of women’s health therapies through Phase 3. Dare’s stock $DARE was up about 28% after announcing the agreement. — Jaimy Lee
2023 Highlights and Anticipated 2024 Milestones XACIATO„¢ (clindamycin phosphate) vaginal gel 2% is available by prescription in the United States to treat bacterial vaginosis under license agreement...
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast...
Data to be presented demonstrate increased frequency of sexual events with Sildenafil Cream, 3.6% use in the Phase 2b RESPOND clinical study, as well as improvement in multiple aspects of the sexual...
SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women™s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST),...
SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced changes in company management which includes the retirement...
SAN DIEGO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women™s health innovation, today announced it has received a grant from the Bill & Melinda Gates...
SAN DIEGO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women™s health innovation, today announced that it has achieved technological proof of concept for...
SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has entered into a royalty-backed financing agreement that provides Daré with $5 million at closing and up to an additional $7 million through three tranches over time at Daré’s option. The financing structure entitles the investor to a percentage of the royalties and milestones to be received by Daré under its global license agreement for XACIATO™ with Organon only until the investor achieves a targeted return on investment.